COVID-19/Vaccine/Financial aspects
 COVID-19/Vaccine/Financial aspects(minister)   | |
|---|---|
The financial aspects of the COVID-19 injections are ultimately of less import from a deep political angle than concerns about safety or about its use as a tool to roll back civil liberties such as freedom of movement.
COVID bailouts
The SDS administered COVID bailouts have involved unprecedented inflation of the money supply, measured in trillions rather than billions. Such sums render even the potential profits from regular injection of billions of people a second order consideration.[1]
Differential Pricing
In March 2021, figures became available on prices paid for Covid vaccines, suggesting that some countries are paying over the odds.
Oxford University and AstraZeneca released a joint statement in November 2020 pledging to make their vaccine available at cost price “in perpetuity” to low and middle-income nations. But South Africa’s Health Ministry revealed in January 2021 that the price being paid there for the Oxford jab was £3.84 - far more than the amount paid by most European nations. In comparison, AstraZeneca are selling the AZD1222 vaccine at £2.17 per jab in the UK, £1.56 in the EU and £2.90 in the USA.[2]
Now compare this to the Pfizer and Moderna Covid vaccine jabs. The UK is paying around £15 per dose for the Pfizer one, and between £24 and £28 per dose for the Moderna one. Israel is paying at least £22 per Pfizer dose (possibly up to £34), the EU £10.60 per dose and the US £14.27 per dose.
The Moderna vaccine development was partly subsidised by the US Government, but nevertheless is costing £10.86 per dose there. The EU are paying £13.03 per Moderna dose and Israel around £18 per dose.
In Russia, the manufacturers of the one-dose Sputnik V jab said in a statement back in November that the cost of its vaccine “for international markets will be less than $10 per dose starting from February 2021”.
“Thus, Sputnik V will be two or more times cheaper than foreign vaccines based on mRNA technology with similar efficacy rates,” the company added. No reliable figures exist on what individual countries have paid for the Russian vaccine, with Hungary and Slovakia becoming the first EU countries to negotiate the purchase of the jab that is yet to be given approval by the European Medicines Agency.
From these figures it is clear that if the AstraZeneca vaccine were to become the major vaccine around the world, it would eat drastically into the profits Pfizer and Moderna are hoping to make. It is therefore not surprising that right from the beginning, there have been 'doubts' generated about the efficacy and safety of the AstraZeneca vaccine, even though later the 'doubts' have been found to be groundless. These drug companies have great sway over Governments and individual leaders and people of 'influence'. None of the same scrutiny has been applied to the Pfizer and Moderna vaccines. But with Pfizer and Moderna charging roughly 5 times per dose compared to AstraZeneca something is not right here.[3]
